[Disseminated strongyloidiasis]

Area of Science:

• Infectious Diseases
• Parasitology
• Tropical Medicine

Background:

• Strongyloidiasis is an intestinal parasitic infection prevalent in tropical and subtropical zones.
• The unique autoinfection cycle allows for persistent infection without re-exposure.
• Immunocompromised patients, especially those on corticotherapy, are at risk for hyperinfection and disseminated disease.

Purpose of the Study:

• To highlight the risks associated with Strongyloidiasis, particularly hyperinfection and disseminated forms.
• To emphasize the critical need for timely diagnosis and treatment in at-risk populations.
• To inform about current treatment recommendations for disseminated strongyloidiasis.

Main Methods:

• Review of Strongyloidiasis pathogenesis, focusing on autoinfection and hyperinfection.
• Characterization of disseminated strongyloidiasis clinical manifestations.
• Evaluation of treatment strategies, including ivermectin efficacy.

Main Results:

• Disseminated strongyloidiasis presents with severe gastrointestinal, respiratory, and systemic involvement, including meningitis and bacteremia.
• The condition has a high fatality rate, estimated at 80% in disseminated cases.
• Ivermectin is recognized as an effective and well-tolerated treatment option.

Conclusions:

• Prompt diagnosis and treatment of Strongyloidiasis are imperative, especially before initiating long-term corticotherapy in susceptible individuals.
• Understanding the autoinfection cycle is key to managing endemic infections.
• Ivermectin is the recommended treatment for disseminated strongyloidiasis due to its effectiveness and tolerability.